VerityRankVerityRank
Back to Rankings
Chongqing Taiji Industry (Group) Co., Ltd.
Manufacturer VerifiedChina

Chongqing Taiji Industry (Group) Co., Ltd.

Taiji

Taiji Group is a leading Chinese pharmaceutical and TCM health products manufacturer headquartered in Chongqing, China, founded in 1993 (predecessor Fuling TCM Factory est. 1972). As a core subsidiary of Sinopharm Group, Taiji achieved annual revenue of CNY 10.5 billion in 2025, with net profit surging 352.38% year-on-year. The company operates dozens of GMP factories across southwestern China, employing over 10,000 staff. Its iconic liquid TCM products such as Huoxiang Zhengqi Oral Liquid command a massive national market share.

Strengths: Dominant production capacity in oral liquid and syrup TCM formulations with billions of units annually; dramatic profit recovery under Sinopharm integration with strong cash flow turnaround from -CNY 631M to +CNY 584M; vertically integrated supply chain from herbal cultivation bases to distribution; iconic OTC brands with decades of consumer trust across China and SE Asia.
Weaknesses: Top-line revenue declined 15.23% in 2025 amid distribution channel restructuring; heavy reliance on seasonal respiratory/gastrointestinal product categories; limited international presence outside traditional markets; aging brand perception among younger demographics.
Read More ▼
ChinaEst. 199310000CNY 10.50 billionDozens of GMP-certified oral liquid and syrup filling lines in Chongqing Fuling, annual capacity in billions of units.SHA: 600129Score 83

Business Nature

Taiji Group operates a fully integrated, self-owned pharmaceutical manufacturing model spanning the complete traditional Chinese medicine value chain—from medicinal herb cultivation bases through industrial-scale extraction, purification, and liquid-filling lines to one of China's largest pharmaceutical distribution networks. Its flagship plants in Chongqing anchor massive capacity for TCM oral liquids led by the Huoxiang Zhengqi portfolio, modern Chinese and Western finished dosage forms, and healthcare products.

Following its integration into the state-owned Sinopharm CNPGC system, Taiji has undergone deep operational restructuring—divesting low-efficiency commercial assets, consolidating production capacity, and enforcing strict cost discipline—which converted a revenue decline into a several-fold net-profit rebound and restored strongly positive operating cash flow in 2025.

Core Business Areas

Traditional Chinese Medicine Oral Liquids & Syrups — Core Business
• Huoxiang Zhengqi Oral Liquid antihistamine/anti-heatstroke
• Jizhi Syrup cough and respiratory relief
• A variety of proprietary Chinese patent medicines in liquid form

Chemical Pharmaceutical Preparations
• Generic cardiovascular and anti-infective agents
• Large-volume parenteral solutions and injections

OTC Health Products
• Digestive health and gastrointestinal remedies
• Cold and flu symptom relief products

Industry Rankings

Corporate Report

Taiji Group is a China-based pharmaceutical and TCM manufacturer headquartered in Chongqing. Founded in 1993 as the successor to a TCM factory established in 1972, the company is now a core subsidiary of state-owned Sinopharm Group. With 2025 revenue of CNY 10.5 billion, Taiji is the largest manufacturer of liquid TCM preparations in China, employing over 10,000 people across dozens of GMP-certified production facilities in southwestern China.

Core Business

Taiji specializes in Traditional Chinese Medicine oral liquids and syrups, with flagship products including Huoxiang Zhengqi Oral Liquid (a household name for heatstroke and gastrointestinal relief) and Jizhi Syrup (respiratory relief). The company also maintains substantial chemical pharmaceutical production capacity across cardiovascular, anti-infective, and parenteral nutrition segments. Its vertically integrated supply chain extends from herbal cultivation bases through extraction facilities to end-product distribution.

Key Strengths

1. The world's largest liquid TCM formulation capacity with annual output in billions of units. 2. Dramatic financial turnaround under Sinopharm integration — net profit surged 352.38% in 2025 with operating cash flow swinging from -CNY 631M to +CNY 584M. 3. Iconic OTC brands with multi-generational consumer trust across China and Southeast Asia. 4. Extensive GMP-certified factory network with heavy investment in automated filling and sterilization lines. 5. Vertically integrated operations from herbal cultivation to finished pharmaceutical distribution.

Challenges & Outlook

Despite dramatic profit recovery, top-line revenue contracted 15.23% in 2025 due to aggressive restructuring of its distribution network. The heavy reliance on seasonal product categories (heatstroke, cold/flu) introduces revenue volatility. Expanding beyond traditional Chinese and SE Asian markets remains a strategic challenge. VerityRank Score of 83/100 reflects strong manufacturing infrastructure and financial health recovery, moderated by revenue concentration risk.

VerityRank Score

83/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

China

Founded

1993

Employees

10000

Factories

Dozens of GMP-certified oral liquid and syrup filling lines in Chongqing Fuling, annual capacity in billions of units.

Listing

SHA: 600129

Categories

Traditional Chinese Medicine & Health Products Manufacturers & SuppliersBiopharmaceuticalComplete Kitchen Solutions BrandsCeiling Integrated System BrandsCardiovascular & Blood Medicines IndustryHousehold Chemical Products BrandsChemical Pharmaceutical Preparations IndustryCeiling Integrated System BrandsTraditional Chinese Medicine & Health Products Brands

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website , Taiji Group 2025 Annual Report, Taiji Group 2025 Financial Results, Taiji Group Official Website, Wikipedia — Taiji Group